Table 1 Clinical–pathologic characteristics of the 22 nonsquamous lung carcinoma patients evaluated in this study
| Â | N (%) |
|---|---|
N | 22 |
Age, median (range) | 58 (42–79) |
Sex | |
 Male | 7 (32%) |
 Female | 15 (68%) |
Previous lines | |
 0 | 4 (18%) |
 1 | 8 (37%) |
 2 | 6 (27%) |
  ≥ 3 | 4(18%) |
Biopsy | |
 Archival | 10 (45%) |
 Baseline | 12 (55%) |
Drug response | |
 CR | 1 (5%) |
 PR | 5 (22%) |
 SD | 7 (32%) |
 PD | 9 (41%) |
Smoking | |
 Current smoker | 8 (36%) |
 Former smoker | 11 (50%) |
 Never smoker | 3 (14%) |
ECOG | |
 0 | 5 (23%) |
 1 | 17 (77%) |
Drug | |
 Nivolumab | 14 (64%) |
 Pembrolizumab | 8 (36%) |
PFS, median | 3.03 |
Lung cancer EGFR status | |
 EGFR mutated | 1 (5%) |
 EGFR wild-type | 21 (95%) |
Lung cancer ALK status | |
 ALK rearranged | 0 (0%) |
 ALK not rearranged | 21 (95%) |
 NA | 1 (5%) |